UCB accepts chairman's resignation

13 December 2022

Belgium’s largest pharma company UCB (Euronext: UCB) yesterday announces that its board of directors has accepted the resignation of Stefan Oschmann as chairman and board member of the firm.

Fiona du Monceau, currently vice chairperson, will take the role of chairwoman ad interim until a new replacement is announced.

Mr Oschmann joined UCB as chairman in 2021 and decided to step down for personal reasons. The board said: “We would like to thank Stefan for sharing with us his strategic business experience in life sciences and wealth of external expertise. We wish him well in his future endeavors.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK